Welcome to the e-CCO Library Archive!

search
                             
search by: 
Filter:
P397. Quality of life of Crohn's disease patients under immunosuppressive therapy in Germany – preliminary results of the DaLi study
Authors:

M. Reinshagen1, B. Bokemeyer2, T. Krummenerl3, M.R. Mross4, P. Nurwakagari5, M. Schwarz5, B.M. Wittig5, 1Klinikum Braunschweig, Dep. of Medicine I, Braunschweig, Germany, 2Gastroenterology Practice, Minden, Germany, 3Gastroenterology Center at Germania Campus, Muenster, Germany, 4Gastroenterology Practice, Berlin, Germany, 5Abbott GmbH & Co. KG, Medical Department, Wiesbaden, Germany

P397

Analysis of Mucosal TNFSF15/TL1A Expression in Korean IBD Patients

Authors:

C.S. Eun*1, D.S. Han1, A.R. Lee1, J.H. Pyo2, Y.H. Oh2

1Hanyang University Guri Hospital, Gastroenterology, Guri, Korea, Republic of, 2Hanyang University Guri Hospital, Pathology, Guri, Korea, Republic of

P398.

Outcome of treatment with biological agents in Crohn's disease: 117 patients in 5 years from a tertiary referral center

Authors:

L. Ramos, A. Hernandez Camba, M. Carrillo Palau, I. Alonso, N. Hernandez Alvarez-Buylla, E. Quintero Carrion, Hospital Universitario de Canarias, Gastroenterology, La Laguna, SantaCruz de Tenerife, Spain

P398. Clinical course of ulcerative colitis and disease extension – the follow-up study in patients with distal ulcerative colitis
P398. Quality of life and nutritional aspects after ileo-cecal resection for Crohn's disease
Authors:

G. Sica1, S. Di Pardo1, E. Iaculli2, R. Scaramuzzo3, C. Fiorani1, R. Pezzuto3, K. Porokhnavets3, A. Di Vizia1, E. Picone1, 1Tor Vergata Roma, Italy, 2Guy's and St Thomas' Hospital, Surgery, London, United Kingdom, 3Tor Vergata, Italy

P398

An Open-label, Pilot Study to Assess Feasibility and Safety of Fecal Microbiota Transplantation in Patients with Mild-Moderate Ulcerative Colitis: preliminary results.

Authors:

F. Scaldaferri*1, S. Pecere1, G. Bruno1, G. Ianiro1, L. Laterza1, V. Gerardi1, L. Lopetuso1, E. Schiavoni1, S. Bibbo1, F. Paroni Sterbini2, M. Sanguinetti2, L. Masucci2, A. Gasbarrini1, G. Cammarota1

1Catholic University of Sacred Heart, Internal Medicine Department, Gastroenterology division, Rome, Italy, 2Catholic University of Sacred Heart, Microbiology, Rome, Italy

P399.

Oral butyrate plus inulin improve serum metabolomic profile and gut microbiota composition in ulcerative colitis and celiac disease

Authors:

S. Sitkin1,2, E. Tkachenko2, T. Vakhitov1, L. Oreshko2, T. Zhigalova2, 1State Research Institute of Highly Pure Biopreparations, Dept. of Applied Microbiology, St. Petersburg, Russian Federation, 2North-Western State Medical University named after I.I. Mechnikov, Dept. of Propaedeutics of Internal Diseases, St. Petersburg, Russian Federation

P399. Microscopic colitis – more interesting than irritating in the post budesonide era
P399. Quality of health care in inflammatory bowel disease at the universitary hospital of Vigo, Spain, measured by questionnaire QUOTE-IBD (Spanish version)
Authors:

L. Sanromán1, M.L. De Castro1, J.M. Rodríguez-Gregori1, J. Martínez Cadilla1, J.R. Pineda1, V. Hernández1, V. Del Campo2, J.I. Rodríguez Prada1, 1Universitary Hospital, Gastroenterology, Vigo, Spain, 2Universitary Hospital, Epidemiology, Vigo, Spain

P399

Short- and long-term outcomes of infliximab treatment for refractory ulcerative colitis and associated prognostic factors: a Japanese single-center study

Authors:

M. Nasuno*, M. Miyakawa, R. Sakemi, H. Tanaka, S. Motoya, A. Imamura

Sapporo-Kosei General Hospital, IBD center, Sapporo, HOKKAIDO, Japan

P400.

Opportunistic infections in anti-TNF treated IBD patients: analysis from three tertiary centers in Romania

Authors:

R.B. Mateescu1, R. Vadan2,3, L. Negreanu4, A. Bengus5, R. Dinu5, B. Busuioc5, B. Cotruta3, M. Diculescu2,6, C. Gheorghe2,6, L. Gheorghe2,6, 1UMF Carol Davila, Bucharest; Colentina Clinical Hospital, Gastroenterology Dept, Bucharest, Romania, 2Fundeni Clinical Institute, Digestive Diseases and Liver Transplantation Center, Bucharest, Romania, 3Centrul de Gastroenterologie si Hepatologie Fundeni, Gastroenterology Dept, Bucharest, Romania, 4UMF Carol Davila, Bucharest; University Hospital, Internal Medicine 2, Bucharest, Romania, 5Colentina Clinical Hospital, Gastroenterology, Bucharest, Romania, 6UMF Carol Davila, Bucharest; Centrul de Gastroenterologie si Hepatologie Fundeni, Gastroenterology Dept, Bucharest, Romania

P400. Immunisation practices in patients with IBD – a wake up call
P400. Psoriasis phenotype in inflammatory bowel disease
Authors:

E. Lolli1, R. Saraceno1, G. Condino1, C. Petruzziello1, S. Onali1, E. Calabrese1, S. Chimenti1, F. Pallone1, L. Biancone1, 1Università Tor Vergata, Roma, Roma, Italy

P400

Setting standards for multi-disciplinary team driven care in inflammatory bowel disease service provision - an expert consensus on key specialists to be involved

Authors:

P. Morar*1, N. Sevdalis2, J. Warusavitarne1, J. Green3, A. Hart1, C. Edwards4, O. Faiz1

1St Mark's Hospital, Colorectal Surgery & IBD Unit, London, United Kingdom, 2Imperial College London, Surgery and Cancer, London, United Kingdom, 3University College Hospitals, Urology and Cancer, London, United Kingdom, 4Torbay Hospital, Gastroenterology, Torbay, United Kingdom

P401.

Outcome of infliximab discontinuation in IBD patients and therapy rechallenging in relapsers: Single centre preliminary data

Authors:

M. Marino, E. Zucchi, M. Fabbro, I. Lodolo, R. Maieron, S. Vadalà, M. Zilli, University Hospital S. M. della Misericordia, Gastroenterology, Udine, Italy

P401. Long term effect of anti-TNFα agents on the lipidemic profile of IBD patients
P401. Pregnancy outcomes in women with inflammatory bowel disease exposed to infliximab
Authors:

Y. Snoeckx1, M. Clark1, A. Geldhof2, J. Morgan2, R. Nissinen2, J. Schlegelmilch3, 1Janssen Research & Development, LLC, United States, 2Janssen Biologics Europe, Netherlands, 3Janssen Services, LLC, United States

P401

Adalimumab as first-line anti-TNF treatment in ulcerative colitis. A "real-life" observational study

Authors:

R. Lorente*1, C. Verdejo1, O. Roncero2, D. López3, P. Robledo4, A. Bouhmidi5, D. Hervías6

1Hospital General Ciudad Real, Gastroenterology, Ciudad Real, Spain, 2Hospital Mancha Centro, Gastroenterology, Alcázar San Juan, Spain, 3Hospital de Llerena, Gastroenterology, Llerena, Spain, 4Hospital San Pedro Alcántara, Gastroenterology, Cáceres, Spain, 5Hospital Santa Bárbara, Gastroenterology, Puertollano, Spain, 6Hospital Virgen Altagracia, Gastroenterology, Manzanares, Spain

P402.

Normalized wall thickness at MRE predicts clinical remission in Crohn's disease after infliximab discontinuation: a 5 years follow-up

Authors:

M.L. Annunziata1, L.G. Papparella1, I. Sansoni2, P. Balestrieri1, M. Cicala1, 1Campus Bio Medico, Gastroenterology, Rome, Italy, 2Campus Bio Medico, Radiology, Roma, Italy

P402. Faecal calprotectin but not serum CRP predicts post-operative endoscopic recurrence of Crohn's disease